Moonlake Immunotherapeutics (MLTX) Stock Price & Analysis
Moonlake Immunotherapeutics (MLTX) rose 0.73% to USD 15.12 as of September 8, 2026 at 17:20 UTC, according to Nexqual real-time market data.
MLTX last closed at USD 15.12; the session ranged USD 14.73–15.43 on volume of 685,474 shares. Market capitalization is —, with a 52-week range of USD 5.95–62.75 (NCM). Source: Nexqual, September 8, 2026 at 17:20 UTC.
Key Statistics (as of September 8, 2026 at 17:20 UTC)
| Price | USD 15.12 |
|---|---|
| Change | ▲ 0.73% (up) |
| Previous Close | USD 15.12 |
| Open | USD 15.12 |
| Day Range | USD 14.73 – 15.43 |
| 52-Week Range | USD 5.95 – 62.75 |
| Volume | 685,474 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (MLTX)
Nexqual's technical model rates MLTX "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of September 8, 2026 at 17:20 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 35.37 (neutral) |
| vs SMA50 | Below (USD 17.72) |
| MACD | -0.78 (negative) |
From Moonlake Immunotherapeutics's Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Intellectual Property As of December 31, 2025, we have the exclusive license to a patent family directed to Il-17 Nanobodies, including SLK, and methods of making and using the same derived from International Patent Application PCT/EP2012/058313, published as WO 2012/156219, entitled "Amino Acid Sequences Directed Against IL-17A, IL-17F and/or IL17-A/F and Polypeptides Comprising the Same".
- In November 2025, we were granted a Type B meeting with the FDA to discuss adequacy of the current clinical evidence package of SLK in HS to support a Biologics License Application ("BLA") and in January 2026, we announced positive feedback from this interaction, confirming that we may establish substantial evidence of effectiveness ("SEE") without additional clinical trials in HS.
- The agreement includes confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates.
Partnerships
- The Merck Healthcare KGaA (Darmstadt, Germany) License Agreement On April 29, 2021, we entered into a license agreement with MHKDG (the "License Agreement").
- Effective July 1, 2021, we entered into a contract manufacturing agreement with Richter Biologics with respect to the manufacture of SLK.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IMVT | Immunovant, Inc. | USD 39.88 | ▲ 1.94% |
| VERA | Vera Therapeutics, Inc. | USD 35.1 | ▲ 0.31% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 84.95 | ▲ 0% |
| JANX | Janux Therapeutics, Inc. | USD 20.06 | ▲ 1.31% |
| KYMR | Kymera Therapeutics, Inc. | USD 119.1 | ▲ 1.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 17:20 UTC. This page is informational and not investment advice.